Diabetes mellitus complicating systemic lupus erythematosus - Analysis of the UCL lupus cohort and review of the literature

Lupus

Volumn 17, Issue 11, 2008, Pages 977-980

  Cortes, Sara ^a   Chambers, S ^b   Jeronimo A ^c   Isenberg, D ^b  

^a INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOSPITAL PEDRO HISPANO   (Portugal)

Author keywords

Diabetes; Nephropathy; Neuropathy; Retinopathy; SLE

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CORTICOSTEROID; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADOLESCENT; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CATARACT; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE PREDISPOSITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LITERATURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT IDENTIFICATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RISK ASSESSMENT; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; MIDDLE AGED; REVIEW;

ADULT; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 61549117121     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308091539     Document Type: Article

References (18)

1. Chambers S Charman SC Rahman A Isenberg DA. Development of additional autoimmune diseases in a multiethnic cohort of patients with reference to damage and mortality. Ann Rheum Dis 2007; 66: 1123-1127.
2. Buyon J Wallace DJ. The use of exogenous estrogens, endocrine system and urogenital tract. In: DJ Wallace BH Hahn, (eds), Dubois' Lupus Erythematosus, sixth ed. Philadelphia: Lippincott, Williams & Wilkins. p. 821-841.
3. Maksimowicz-McKinnon K Manzi S. Cardiovascular manifestations of lupus. In: DJ Wallace BH Hahn, (eds), Dubois' Lupus Erythematosus, seventh ed. Philadelphia: Lippincott; 2007. p. 674.
4. Tan EM Cohen AS Fries JF. et al The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
5. American Diabetes Association. Diagnosis and Classification of Diabetes mellitus. Diabetes Care 2007; 30: S42-S47.
6. Adler M Chambers S Edwards C. et al An assessment of renal flare in an SLE cohort with special reference to ethnicity overall 25 year period. Rheumatology 2006; 45: 1144-1147.
7. Marto N Bertolaccini ML Calabuig E. et al Anti-C1q antibodies in nephritis:cOrrelation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 444-448.
8. Ritz E. Diabetic nephropathy. Saudi J Kidney Dis Transpl 2006; 17: 481-490.
9. Tone A Shikata K Matsuda M. et al Clinical features of non-diabetic renal diseases in patients with type 2 diabetes. Diabetes Res Clin Pract 2005; 69: 237-242.
10. West SG. The nervous system. In: DJ Wallace BH Hahn, (eds), Dubois' Lupus Erythematosus, sixth ed. Philadelphia: Lippincott; 2007. p. 695.
11. Bril V. Status of current clinical trials in diabetic polyneuropathy. Can J Neurol Sci 2001; 28: 191-198.
12. Omdal R Loseth S Torbergsen T. et al Peripheral neuropathy in systemic lupus erythematosus - a longitudinal study. Acta Neurol Scand 2001; 103: 386-391.
13. Grassi G. Diabetic retinopathy. Minerva Med 2003; 94: 419-435.
14. Au A O'Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: Associations, visual outcomes, complications and treatment. Clin Exp Ophthalmol 2004; 32: 87-100.
15. Trojet S Loukil I El Afrit MA. et al Bilateral retinal vascular occlusion during antiphospholipid antibody syndrome: A case report. J Fr Ophtalmol 2005; 28: 503-507.
16. Ermakova NA Alekberova ZS Kosheleva NM Reshetniak TN. Characteristics of retinal vascular involvement in systemic lupus erythematosus. Vestn Oftalmol 2001; 117: 21-24.
17. Bruce I. 'Not only ... but also': Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatol 2005; 44: 1492-1502.
18. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007; 67: 997-1026.